Ceritinib (LDK378)
CLDK378A2407
Phase 2 small_molecule terminated
Quick answer
Ceritinib (LDK378) for Tumors With Aberrations in ALK is a Phase 2 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Tumors With Aberrations in ALK
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated